



---

an Open Access Journal by MDPI

---

Impact Factor 1.1

CiteScore 2.3

# Journal of Molecular Pathology

[mdpi.com/  
journal/  
jmp](https://mdpi.com/journal/jmp)



# Message from the Editor-in-Chief

The *Journal of Molecular Pathology* is an open access journal that was established in 2020. The journal reveals genomic secrets so that they may be brought forward to the overall community of modern physicians and scientists. We invite you to explore our latest publications and consider *JMP* for your next research submission. Together, we can drive the future of molecular pathology.

---

## Editor-in-Chief

Prof. Dr. Giancarlo Troncone

---

## Aims

*Journal of Molecular Pathology* (*JMP*, ISSN 2673-5261) is an international, peer-reviewed open-access journal. In the era of precision and personalized medicine, molecular pathology is transforming conventional histopathology and cytopathology. The focus of this journal is on the need for pathologists to embrace such change and to develop molecular pathology even further. This journal will provide a unique forum for the interaction and dissemination of original research and educational information relevant to the practice of molecular pathology and its related disciplines.

*Journal of Molecular Pathology* publishes reviews, regular research papers, and short communications as well as Special Issues on particular subjects. It aims to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, the journal has no restrictions regarding the length of papers submitted. Full experimental details should be provided so that the results can be reproduced.

---

## Scope

*Journal of Molecular Pathology* covers every topic related to modern histopathology and cytopathology, predictive pathology, and molecular cytopathology. Thus, our major focus is on pre-analytical and analytical issues and the interpretation of biomarker testing in the field of diagnostic and predictive molecular pathology.

Topics of interest include but are not limited to:

- Modern histopathology;
- Modern cytopathology;
- Pre-analytical cyto- and histo-pathological issues;
- Tissue diagnostic molecular pathology;
- Tissue predictive molecular pathology;
- Body fluids molecular pathology;
- Immunotherapy biomarkers;
- Molecular tumor boards;
- Translational pathology research;
- Digital pathology;
- Molecular pathology training programs;
- Next-generation technologies in molecular pathology;
- Agnostic biomarkers;
- Liquid biopsy;
- Next-generation sequencing (NGS).

---

## Author Benefits

### Open Access

Unlimited and free access for readers

### No Copyright Constraints

Retain copyright of your work and free use of your article

### Thorough Peer-Review

### Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

### No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

### Rapid Publication

A first decision is provided to authors approximately 28.2 days after submission; acceptance to publication is undertaken in 6.8 days (median values for papers published in this journal in the first half of 2025)

**MDPI is a member of**

**CASPA**




**STM<sup>1</sup>**



**SPARC\***  
Europe



**DOAJ**



**ORCID**



**Editorial Office**

[jmp@mdpi.com](mailto:jmp@mdpi.com)

**MDPI**

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[mdpi.com](http://mdpi.com)

July 2025

